Protectan Technology: Entolimod (CBLB502) & CBLB612
1. Brackett CM, Koiouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV. 2015 Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. PNAS 2016 Feb 1. pii: 201521359. (PMID: 26831100)
2. Yang H, Brackett C, Morales-Tirado V, Li Z, Zhang Q, Wilson M, Benjamin C, Harris W, Waller V, Gudkov AV, Burdelya L, Grossniklaus H. 2015 The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget 2015 Dec 8. doi: 10.18632/oncotarget.6500
3. Krivokrysenko V, Toshkov I, Gleiberman A, Krasnov P, Shyshynova I, Bespalov I, Maitra R, Narizhneva N, Singh V, Whitnall M, Purmal A, Shakhov A, Gudkov AV, Feinstein E. 2015. The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates. PLoS One Sep 15;10(9):e0135388. doi: 10.1371/journal.pone.0135388 (PMCID: PMC4569586)
4. Leigh ND, Bian G, Ding X, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X. 2014. A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity. PLoS One Jan 14;9(1):e85587. doi: 10.1371/journal.pone.0085587. eCollection 2014. (PMID: 24454895)
5. Kojouharov BM, Brackett CM, Veith JM, Johnson CP, Gitlin II, Toshkov IA, Gleiberman AS,Gudkov AV, Burdelya LG. 2014. Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget. Feb 15;5(3):802-14.. (PMID:24583651)
6. Chow CP, Faqi AS. Developmental toxicity study of CBLB502 in Wistar rats. Reprod Toxicol. 2014 Jul;46:12-9. doi: 10.1016/j.reprotox.2014.02.007. Epub 2014 Mar 3. (PMID: 24602561)
7. Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS, Aygun-Sunar S, Veith J, Johnson C, Haderski GJ, Stanhope-Baker P, Allamaneni S, Skitzki J, Zeng M, Martsen E, Medvedev A, Scheblyakov D, Artemicheva NM, Logunov DY, Gintsburg AL, Naroditsky BS, Makarov SS, Gudkov AV. 2013.Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proceedings of the National Academy of Science. 2013 May 14;110(20):E1857-66. doi: 10.1073/pnas.1222805110. Epub 2013 Apr 29. (PMID: 23630282)
8. Ding X, Bian G, Leigh ND, Qiu J, McCarthy PL, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X., 2012.A TLR5 Agonist Enhances CD8+ T Cell-Mediated Graft-versus-Tumor Effect without Exacerbating Graft-versus-Host Disease. J Immunol 189(10):4719-4727. doi: 10.4049/jimmunol.1201206. Epub 2012 Oct 8 (PMID: 23045613)
9. Krivokrysenko V, Shakhov A, Singh V, Bone F, Kononov Y, Shyshynova I, Cheney A, Maitra R, Purmal A, Whitnall M, Gudkov AV, Feinstein E., 2012. Identification of G-CSF and IL-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure. Journal Pharmacology and Experimental Therapeutics July 26 (e-pub ahead of print) (PMID: 22837010)
10. Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, Wilson IA., 2012. Structural Basis of TLR5-Flagellin Recognition and Signaling. Science 335:859-864 (PMID: 22344444)
• Mueller, K., 2012. Flagellin Takes Its Toll. Science. Editor’s Choice 5:212 p ec62
11. Singh VK, Ducey EJ, Fatanmi OO, Singh PK, Brown DS, Purmal A, Shakhova VV, Gudkov AV, Feinstein E, Shakhov A., 2012. CBLB613: A TLR2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. Radiation Research 177, 628-642 (PMID: 22175300)
12. Shakhov AN, Singh VK, Bone F, Cheney A, Kononov Y, Krasnov P, Bratanova-Toshkova TK, Shakhova VV, Young J, Weil MM, Panoskaltsis-Mortari A, Orschell CM, Baker PS, Gudkov A, Feinstein E.,2012. Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2). PLoS One, 7(3):e33044. Epub 2012 Mar 27(PMID: 22479357)
13. Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier D, Krivokrysenko VI, Feinstein E, Gudkov AV., 2011. Toll-like Receptor 5 Agonist Protects Mice from Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy. International Journal of Radiation Oncology, Biology and Physics, Oct.14 (e-pub ahead of print) (PMID: 22000579)
14. Fukuzawa N, Petro M, Baldwin WM 3rd, Gudkov AV, Fairchild RL., 2011. A TLR5 agonist inhibits acute renal ischemic failure. Journal of Immunology 187: 3831-3839 (PMID: 21890657)
15. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E, Gudkov AV., 2008. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320:226-230 (PMID: 18403709)
Other Supporting Publications
16. Howell BA, Siler SQ, Shoda LK, Yang Y, Woodhead JL, Watkins PB. A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial. CPT Pharmacometrics Syst Pharmacol. 2014 Feb 5;3:e98. doi: 10.1038/psp.2013.74. (PMID: 24500662)
17. Chen H, Wang ZD, Chen MS, Zhang XQ, Shen LP, Zhang JX, Chen Y. Activation of Toll-like receptors by intestinal microflora reduces radiation-induced DNA damage in mice. Mutat Res Genet Toxicol Environ Mutagen. 2014 Nov 1;774:22-8. doi:10.1016/j.mrgentox.2014.09.001. Epub 2014 Sep 16. (PMID: 25440907)
18. Hossain MS, Ramachandiran S, Gewirtz AT, Waller EK. Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. PLoS One. 2014 May 30;9(5):e96165. doi: 10.1371/journal.pone.0096165. eCollection 2014. (PMID: 24879439)
19. Lu J., Sun PD. 2012. The Structure of the TLR5-Flagellin Complex: A New Mode of Pathogen Detection, Conserved Receptor Dimerization for Signaling. Science Signaling 5, (pe 11) (PMID: 22434932)
20. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D., 2011. Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth. Cancer Research DOI:10.1158/0008-5472.CAN-10-1993 (PMID: 21427357)
21, Gudkov AV, Komarova EA. 2010. Pathologies associated with the p53 response. Cold Spring Harb Perspect Biol. 2(7):a001180. 2(7):a001180. Epub 2010 Apr 7 (PMID: 20595398)
22. Bhattacharjee, Y. 2008. Medicine. Drug bestows radiation resistance on mice and monkeys. Science 320:163 (PMID: 18403680)
23. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV., 2006. Small molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nature Chemical Biology, 2006 July 23; 2(7): 1-5 (PMID: 16862141)
24. Komarova EA, Kondratov RV, Wang K, Christov K, Golovkina TV, Goldblum JR, Gudkov AV., 2004. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 23(2): 3265-3271 (PMID: 15064735)
25. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV., 1999. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 285(2): 1733-1737 (PMID: 10481009)
Curaxin Technology: CBL0137 & Predecessor
26. Burkhart C, Fleyshman D, Kohrn R, Commane M, Garrigan J, Kurbatov V, Toshkov I, Ramachandran R, Martello L, Gurova KV. 2014. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget Nov 30;5(22):11038-53. (PMID: 25402820)
27. Garcia H, Miecznikowski JC, Safina A, Commane M, Ruusulehto A, Kilpinen S, Leach RW, Attwood K, Li Y, Degan S, Omilian AR, Guryanova O, Papantonopoulou O, Wang J, Buck M, Liu S, Morrison C, Gurova KV, 2013. Facilitates Chromatin Transcription Complex Is an “Accelerator” of Tumor Transformation and Potential Marker and Target of Aggressive Cancers. Cell Reports. Jul 2. pii: S2211-1247(13)00291-X. doi: 10.1016/j.celrep.2013.06.013. (PMID: 23831030)
28. Koman IE, Commane M, Paszkiewicz G, Hoonjan B, Pal S, Safina A, Toshkov I, Purmal AA, Wang D, Liu S, Morrison C, Gudkov AV and Gurova KV., 2012. Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice. Cancer Prevention Research, Aug;5(8):1025-35. (PMID:22689915)
29. Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, Gudkov AV, Gurova KV., 2011.Curaxins: Anticancer Compounds that Simultaneously Suppress Nf-kB and Activate p53 by Targeting FACT. Science Translational Medicine 3(95):95ra72 (PMID: 21832239)
30. Gudkov AV, Gurova KV, Komarova EA. Inflammation and p53: A Tale of Two Stresses. Genes Cancer. 2011 Apr;2(4):503-16 (PMID: 21779518)
31. Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, Gasparian AV, Banerjee AK, Almasan A, Fairchild RL, Gudkov AV., 2009. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 8(23):3960-3970 (PMID: 19901558)
32. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV., et al., 2009.9Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 28(8): 1151-1161 (PMID: 19137016)
33. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV., 2005. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proceedings of the National Academy of Science 102(48):17448-17453 (PMID: 16287968)
Other Supporting Publications
34. Draetta GF, Depinho RA. 2011. Cancer drug discovery faces the FACT. Science Translational Medicine 3(95):95ps34 (PMID: 21832237)
35. Gasparian AV, Neznanov N, Jha S, Galkin O, Moran JJ, Gudkov AV, Gurova KV, Komar AA., 2010. Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugs. Journal of Virology 84 (18): 9390-9397 (PMID: 20631142)
36. Mollapour M, Neckers L., 2010. Quinacrine: New anti-tumor application for an old anti-malaria drug. Cell Cycle 9(2):228. Epub 2010 Jan 15. (PMID: 20061796)
37. Chau CH, Figg WD., 2009. New tricks from an old drug: a role for quinacrine in anti-cancer therapy? Cell Cycle 8(24):4024-5. Epub 2009 Dec 15. (PMID: 19959937)
38. Dai C, Whitesell L, Rogers AB, Lindquist S., 2007. Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis. Cell 130: 1005-1018 (PMID: 17889646)
39. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV., 2006. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes & Development 20(2):236-52 (PMID: 16418486)
40. Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, Nedospasov SA, Hazen SL, Feinstein E, Gudkov AV., 2005. p53 is a suppressor of inflammatory response in mice. FASEB Journal 19(8):1030-1032 (PMID: 15811878) http://www.ncbi.nlm.nih.gov/pubmed/15811878
41. Gudkov AV, Komarova EA., 2005. Prospective therapeutic applications of p53 inhibitors. Biochemical and Biophysical Research Communications 331(1): 726-736 (PMID: 15865929)
Cleveland BioLabs, Inc.
73 High Street
Buffalo, NY 14203
Permission to Use
Intellectual Property Rights
Certain Site Content
Any health or medical information included on the Site is for informational purposes only and is not, and is not intended to be, a medical diagnosis or a replacement for advice given by a physician or other healthcare professional, and none of the information included on the Site constitutes, or is intended to constitute, investment advice. Product candidates in development described on the Site have not been found safe or effective by any regulatory agency and are not approved for any use other than in certain clinical trials. Information included on the Site regarding any product approved for marketing is qualified in its entirety by reference to the full prescribing information for such product.
The Site may include certain third-party information or content. This third-party information or content does not represent the views, opinions or beliefs of Cleveland BioLabs, and Cleveland BioLabs disclaims any responsibility for any such third-party information or content.
This Site contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors.
These factors include, among others, the Company’s history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company’s need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company’s R&D grants and contracts and its ability to win additional funding under such grants and contracts; the Company’s failure to successfully and timely develop new products; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company’s inability to obtain regulatory approval in a timely manner or at all; the Company’s collaborative relationships and the financial risks related thereto; the Company’s ability to comply with its obligations under license agreements; the potential for significant product liability claims; and the Company’s ability to comply with various safety, environmental and other governmental regulations. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the “Risk Factors” and “Forward-Looking Statements” described in the Company’s periodic filings with the Securities and Exchange Commission.
You may use the Site to contact Cleveland BioLabs with inquiries about information included on the Site. When you provide any information to Cleveland BioLabs, you agree to provide true, accurate, complete and current information and not to use a false or misleading name or a name that you are not authorized to use. You shall not transmit information to or through the Site that: (i) infringes or violates any intellectual property right or privacy right of any third party; or (ii) contains confidential information or trade secrets belonging to you or any third party. Cleveland BioLabs does not want to receive any such information. Any ideas, suggestions, information, know-how, material or other content transmitted to or through the Site will be deemed to include a royalty-free, perpetual, irrevocable, transferable, worldwide, nonexclusive right and license for Cleveland BioLabs to adopt, publish, reproduce, disseminate, transmit, distribute, copy, use, create derivative works, display, (in whole or part), or act thereon without any approval or consideration from you, in any form, medium, or technology now known or later developed for the full term of any rights that may exist therein. Cleveland BioLabs makes no promise, express or implied, that it will not use any such idea, suggestion, information, know-how, material or other content for its own purposes, which may include reproduction, publication, broadcast and posting.
The Site may provide hypertext links to other web sites that are not owned or controlled by Cleveland BioLabs. These links are provided for your convenience only. These web sites are controlled by third parties that Cleveland BioLabs does not control. Accordingly, Cleveland BioLabs expressly disclaims any responsibility for the content of such web sites, for the accuracy or reliability of the information thereon and for the quality of products or services provided thereby or advertised thereon. No link included on the Site constitutes an endorsement of Cleveland BioLabs of any content of, information on or product or service provided by, or advertised on, any such web site. If you choose to hyperlink to another web site, you do so at your own risk. Cleveland BioLabs reserves the right to terminate any hypertext link without notice.
You are prohibited from violating or attempting to violate the security of the Site. Without limiting the generality of the foregoing, you may not: (i) access data or materials that are not intended for you; (ii) log, or attempt to log, into a server or account that you are not authorized to access; or (iii) attempt to probe, scan or test the vulnerability of the Site. Violations of system or network security may result in civil or criminal liability. Cleveland BioLabs reserves the right to investigate any suspected violation of this section and to involve and cooperate with law enforcement authorities in prosecuting any party who participates in any such violation.
Compliance with Laws
You may use the Site only for lawful purposes. You agree that you will, at all times, comply with all applicable local, state, national and international laws, statutes, rules, regulations, ordinances and the like applicable to your use of the Site.
Disclaimers; Limitation of Liability
THE SITE IS PROVIDED “AS IS” AND “AS AVAILABLE,” WITHOUT WARRANTIES OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE BY LAW, CLEVELAND BIOLABS DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY (INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT).
Cleveland BioLabs does not warrant that the Site will be uninterrupted, secure or error-free, that defects will be corrected, or that the Site or the server that makes it available are or will be free of viruses or other harmful components. Information included on the Site may be incomplete, outdated or inaccurate and may contain typographical errors. Cleveland BioLabs makes no commitment to update the information included on the Site. YOUR USE OF THE SITE IS AT YOUR OWN RISK. UNDER NO CIRCUMSTANCES SHALL CLEVELAND BIOLABS OR ANY OF ITS DIRECTORS, OFFICERS, EMPLOYEES, OR AGENTS BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES (INCLUDING DAMAGES FOR LOSS OF BUSINESS, REVENUE OR PROFITS AND THE LIKE) ARISING OUT OF OR IN CONNECTION WITH YOUR USE OF THE SITE OR YOUR RELIANCE ON ANY INFORMATION CONTAINED ON THE SITE, WHETHER BASED ON CONTRACT, NEGLIGENCE, TORT, STRICT LIABILITY OR ANY OTHER BASIS, EVEN IF CLEVELAND BIOLABS HAS BEEN ADVISED OF, OR SHOULD HAVE KNOWN OF, THE POSSIBILITY OF SUCH DAMAGES. Because some jurisdictions do not permit the exclusion of certain warranties or the limitation of liability as set forth above, such exclusions and limitations may not apply to you.
The information provided on the Site is intended for United States audiences only. Cleveland BioLabs makes no representation that the information on the Site is appropriate or available for use in other locations, and access or use of the Site from territories in which the content of the Site may be illegal is prohibited. If you wish to access or use the Site from outside of the United States, you do so on your own initiative and you are responsible for complying with applicable laws and regulations. You should not construe anything on the Site as a promotion of, or solicitation for, any product or product candidate that is not authorized by the laws and regulations of the country in which you are located.
Collection of Personal Information
We collect Personal Information that you submit to us voluntarily through our website. The types of Information we collect are:
For visitors who email us directly via an email hyperlink:
- Email address
- Any content included in the email
For all visitors:
- As you navigate our website, certain passive information will also be collected, including Internet Protocol addresses, cookies and navigational data. This type of information will be used for the purposes of gathering data to provide improved administration of our website, and to improve the quality of your experience when interacting with our website.
Use of Personal Information
In general, Personal Information you submit to us is used either to respond to requests that you make, or to aid us in serving you better.
Disclosure of Personal Information
We do not sell your Personal Information or share your information with other companies or organizations without your consent. The content of any communications you send to us is non-confidential, and we are under no obligation to refrain from reproducing, publishing, or otherwise using such content in any way or for any purpose. We will not reproduce, publish, or otherwise use your Personal Information in connection with such content. We may, however, reproduce or use your Personal Information in connection with any resume you submit to us for employment recruiting purposes. We are free to use the content of any such communications (excluding any resume you submit to us), including any ideas, inventions, concepts, techniques, or know-how disclosed therein, for any purpose including developing, manufacturing, and/or marketing goods or services.
Our website is not designed for children under the age of 13. We will not deliberately gather Personal Information about visitors in this age group, and do not collect any information on this website with respect to age.
Links to Other Sites
Cleveland BioLabs, Inc.
73 High St.
Buffalo, NY 14203
This policy was last updated on June 15, 2012.